Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNCE NASDAQ:CTMX OTCMKTS:CXRXF NASDAQ:EOLS NASDAQ:SPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ACTMXCytomX Therapeutics$1.98-2.9%$2.16$0.40▼$3.10$336.42M2.182.39 million shs3.65 million shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsEOLSEvolus$6.29-2.0%$7.78$5.71▼$17.82$415.28M1.07874,581 shs2.32 million shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CTMXCytomX Therapeutics-2.94%-1.00%+0.51%-14.66%+66.39%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%EOLSEvolus-2.02%-12.52%-13.00%-32.22%-61.22%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ACTMXCytomX Therapeutics$1.98-2.9%$2.16$0.40▼$3.10$336.42M2.182.39 million shs3.65 million shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsEOLSEvolus$6.29-2.0%$7.78$5.71▼$17.82$415.28M1.07874,581 shs2.32 million shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CTMXCytomX Therapeutics-2.94%-1.00%+0.51%-14.66%+66.39%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%EOLSEvolus-2.02%-12.52%-13.00%-32.22%-61.22%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCEConcert Pharmaceuticals 0.00N/AN/AN/ACTMXCytomX Therapeutics 3.20Buy$5.30167.68% UpsideCXRXFADVANZ PHARMA 0.00N/AN/AN/AEOLSEvolus 2.75Moderate Buy$21.25237.84% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EOLS, CTMX, CNCE, SPPI, and CXRXF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.509/16/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/8/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/6/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.008/6/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $20.008/6/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$22.007/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58CTMXCytomX Therapeutics$138.10M2.36$0.35 per share5.64($0.01) per share-198.00CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63EOLSEvolus$266.27M1.53N/AN/A$0.09 per share69.89SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ACTMXCytomX Therapeutics$31.87M$0.563.54N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)CXRXFADVANZ PHARMA-$74.86MN/AN/A∞N/A-15.31%N/A-4.38%N/AEOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCEConcert PharmaceuticalsN/A9.039.03CTMXCytomX TherapeuticsN/A4.204.20CXRXFADVANZ PHARMA257.042.391.61EOLSEvolus22.002.271.86SPPISpectrum PharmaceuticalsN/A2.712.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCEConcert Pharmaceuticals70.63%CTMXCytomX Therapeutics67.77%CXRXFADVANZ PHARMAN/AEOLSEvolus90.69%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipCNCEConcert Pharmaceuticals11.33%CTMXCytomX Therapeutics6.60%CXRXFADVANZ PHARMAN/AEOLSEvolus5.90%SPPISpectrum Pharmaceuticals2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableEOLSEvolus17064.68 million60.87 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableEOLS, CTMX, CNCE, SPPI, and CXRXF HeadlinesRecent News About These CompaniesSPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals,September 19 at 10:58 PM | reflector.comRSPPI FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class ...September 19 at 5:57 PM | cantechletter.comCSPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPISeptember 19 at 5:26 PM | globenewswire.comSPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24thSeptember 19 at 10:41 AM | globenewswire.comSpectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens BermanSeptember 19 at 10:03 AM | globenewswire.comDEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025September 18 at 5:06 PM | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure ...September 16, 2025 | bakersfield.comBROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPISeptember 16, 2025 | globenewswire.comSPECTRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comSpectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPISeptember 15, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15, 2025 | prnewswire.comDEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025September 12, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 10, 2025 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPISeptember 10, 2025 | globenewswire.comSPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025September 8, 2025 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPISeptember 5, 2025 | globenewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 5, 2025 | prnewswire.comSpectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPISeptember 2, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 2, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitAugust 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEOLS, CTMX, CNCE, SPPI, and CXRXF Company DescriptionsConcert Pharmaceuticals NASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.CytomX Therapeutics NASDAQ:CTMX$1.98 -0.06 (-2.94%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.99 +0.01 (+0.51%) As of 09/19/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Evolus NASDAQ:EOLS$6.29 -0.13 (-2.02%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.36 +0.07 (+1.03%) As of 09/19/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
